Vanguard Group Inc Seelos Therapeutics, Inc. Transaction History

Vanguard Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.16 - $1.64 $28,012 - $287,127	175,078 Added 3.5%	5,172,726 $931,000
Q2 2023 Aug 14, 2023	SELL	$0.66 - $1.22 $12,601 - $23,293	-19,093 Reduced 0.38%	4,997,648 $6 Million
Q4 2022 Feb 10, 2023	BUY	$0.66 - $1.34 $1,584 - $3,217	2,401 Added 0.05%	5,016,741 $3.41 Million
Q3 2022 Nov 14, 2022	BUY	$0.65 - $1.41 $56,543 - $122,655	86,990 Added 1.77%	5,014,340 $5.16 Million
Q2 2022 Aug 12, 2022	SELL	$0.51 - $0.93 $369,055 - $672,983	-723,638 Reduced 12.81%	4,927,350 $3.35 Million

Q1 2022 May 13, 2022	BUY	$0.84 - $1.71 $423,784 - $862,703	504,505 Added 9.8%	5,650,988 $4.74 Million
Q4 2021 Feb 14, 2022	SELL	$1.59 - $2.38 $49,321 - $73,827	-31,020 Reduced 0.6%	5,146,483 $8.39 Million
Q3 2021 Nov 12, 2021	BUY	$1.69 - $2.89 $637,434 - $1.09 Million	377,180 Added 7.86%	5,177,503 $12.5 Million
Q2 2021 Aug 13, 2021	BUY	$2.64 - $6.32 $12.7 Million - $30.3 Million	4,800,323 New	4,800,323 $12.7 Million

40.5K

Ticker SEEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 106,691,000
Market Cap $59.7M
Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.